Walter Roland B, Potter Victoria, Craddock Charles
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Blood. 2025 Jun 12;145(24):2847-2856. doi: 10.1182/blood.2024024247.
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults aged ≥70 years with acute myeloid leukemia. However, although potentially curative, nonrelapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving nontransplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.
降低强度预处理方案的出现、移植物抗宿主病预防措施的改进以及更好的支持性护理，使得年龄≥70岁的急性髓系白血病成年患者越来越多地能够接受异基因造血细胞移植（allo-HCT）。然而，尽管allo-HCT有潜在的治愈效果，但非复发死亡率和复发仍是治疗失败的主要原因，这凸显了优化患者选择和移植策略的重要性。与此同时，不断发展的非移植疗法和移植技术要求开展前瞻性试验，重新审视allo-HCT的作用及其最佳实施方式。
